Suppr超能文献

血管紧张素受体拮抗作用和血管紧张素转换酶抑制作用可改善高血压性心肌病的舒张功能障碍以及肌浆网中Ca(2+)-ATP酶的表达。

Angiotensin receptor antagonism and angiotensin converting enzyme inhibition improve diastolic dysfunction and Ca(2+)-ATPase expression in the sarcoplasmic reticulum in hypertensive cardiomyopathy.

作者信息

Flesch M, Schiffer F, Zolk O, Pinto Y, Stasch J P, Knorr A, Ettelbrück S, Böhm M

机构信息

Klinik III für Innere Medizin der Universität zu Köln, Germany.

出版信息

J Hypertens. 1997 Sep;15(9):1001-9. doi: 10.1097/00004872-199715090-00011.

Abstract

BACKGROUND

Hypertensive cardiomyopathy is a major risk factor for the development of chronic heart failure.

OBJECTIVE

To investigate whether treatment with an angiotensin converting enzyme inhibitor (ACEI) or with an angiotensin type 1 receptor antagonist (AT1-RA) is sufficient to prevent the development of hypertensive cardiomyopathy and cardiac contractile dysfunction. Special emphasis was placed on the effects of both treatments on sarcoplasmic reticulum Ca(2+)-ATPase (SERCA 2a) gene expression as a major cause of impaired diastolic cardiac relaxation.

METHODS AND RESULTS

Eight-week-old rats harboring the mouse renin 2d gene [TG(mREN2)27] were treated for 8 weeks with 100 mg/kg captopril (Cap) in their food and 100 mg/kg of the AT1-RA Bay 10-6734 (Bay) in their food. Untreated TG(mREN2)27 and Sprague-Dawley rats (SDR) were used as controls. Both treatment regimens normalized the left ventricular weight, which was increased significantly (P < 0.001) in TG(mREN2)27. Both treatments normalized the left ventricular end-systolic and end-diastolic pressures, which were significantly (P < 0.001) higher in TG(mREN2)27 than they were in SDR, and they improved the velocity of the decrease in pressure [P < 0.05, Bay and Cap versus TG(mREN2)27]. Decreased left ventricular SERCA 2a mRNA and protein levels and increased atrial natriuretic peptide messenger RNA levels were normalized by Bay and Cap treatments (P < 0.05, Bay and Cap versus TG(mREN2)27, by Northern and Western blotting). According to radioimmunoassay and an enzyme assay, respectively, Bay, but not Cap, increased plasma angiotensin I concentrations and the renin activity above normal levels (P < 0.05), whereas myocardial angiotensin II concentrations (determined by radioimmunoassay), which were significantly (P < 0.05) increased in TG(mREN2)27, were normalized equally by Bay and Cap.

CONCLUSIONS

In renin-induced hypertensive cardiomyopathy, left ventricular diastolic dysfunction occurs at the stage of compensated myocardial hypertrophy. The decreased left ventricular relaxation velocity might be due to reduced SERCA 2a gene expression. In this model of hypertensive cardiomyopathy, AT1-RA and ACEI treatments are similarly effective at reducing the arterial pressure, preventing myocardial hypertrophy and diastolic contractile dysfunction. Normalization of SERCA 2a gene expression, either by AT1-RA or by ACEI treatment, might contribute to the improvement in diastolic function.

摘要

背景

高血压性心肌病是慢性心力衰竭发生的主要危险因素。

目的

研究使用血管紧张素转换酶抑制剂(ACEI)或血管紧张素1型受体拮抗剂(AT1-RA)进行治疗是否足以预防高血压性心肌病和心脏收缩功能障碍的发生。特别强调了这两种治疗方法对肌浆网Ca(2+)-ATP酶(SERCA 2a)基因表达的影响,该基因表达是舒张期心脏舒张功能受损的主要原因。

方法与结果

对携带小鼠肾素2d基因[TG(mREN2)27]的8周龄大鼠,在其食物中添加100 mg/kg卡托普利(Cap)或100 mg/kg的AT1-RA贝那普利10-6734(Bay)进行为期8周的治疗。未治疗的TG(mREN2)27大鼠和Sprague-Dawley大鼠(SDR)用作对照。两种治疗方案均使左心室重量恢复正常,TG(mREN2)27大鼠的左心室重量显著增加(P < 0.001)。两种治疗均使左心室收缩末期和舒张末期压力恢复正常,TG(mREN2)27大鼠的这两项压力显著高于SDR大鼠(P < 0.001),并且它们改善了压力下降速度[P < 0.05,Bay和Cap与TG(mREN2)27相比]。Bay和Cap治疗使左心室SERCA 2a mRNA和蛋白水平降低以及心房利钠肽信使RNA水平升高的情况恢复正常(P < 0.05,通过Northern和Western印迹法检测,Bay和Cap与TG(mREN2)27相比)。分别根据放射免疫测定和酶测定,Bay可使血浆血管紧张素I浓度和肾素活性升高至正常水平以上(P < 0.05),而Cap则不能,而TG(mREN2)27大鼠中显著升高(P < 0.05)的心肌血管紧张素II浓度(通过放射免疫测定),Bay和Cap均可使其恢复正常。

结论

在肾素诱导的高血压性心肌病中,左心室舒张功能障碍发生在代偿性心肌肥厚阶段。左心室舒张速度降低可能是由于SERCA 2a基因表达减少所致。在这种高血压性心肌病模型中,AT1-RA和ACEI治疗在降低动脉压、预防心肌肥厚和舒张期收缩功能障碍方面同样有效。通过AT1-RA或ACEI治疗使SERCA 2a基因表达恢复正常可能有助于舒张功能的改善。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验